低剂量CT筛查阴性后的肺癌发病与死亡风险
基于中国国家肺癌筛查项目的前瞻性队列研究,纳入269173名40至74岁参与者,中位随访8.61年。与未筛查组相比,筛查阴性组的肺癌发病风险(HR 0.80,95%CI 0.65-0.97)和全因死亡风险(HR 0.77,95%CI 0.70-0.85)显著降低,但肺癌特异性死亡风险无显著差异(HR 0.88,95%CI 0.69-1.12)。筛查阴性组的长期风险与低风险人群相当,支持风险分层随访而非统一每年复筛。
要点
- 筛查阴性者肺癌发病和全因死亡风险低于未筛查者,但肺癌特异性死亡无显著差异。
- 筛查阴性者长期风险与低风险人群相当,支持风险分层随访。
- 当前吸烟且筛查阴性者长期肺癌发病风险高于低风险组。
核心结论
- 低剂量CT筛查阴性者的肺癌发病、死亡及全因死亡长期风险与低风险人群相当,支持风险分层随访。
研究设计与样本
- 前瞻性队列研究,数据来自中国国家肺癌筛查项目2012至2019年省级项目,纳入269173名40至74岁参与者。
- 参与者分为未筛查、筛查阴性、筛查阳性或低风险组,采用逆概率加权整合Cox比例风险模型估计风险比。
主要发现
- 中位随访8.61年,共发生3173例肺癌和2083例肺癌死亡。
- 与未筛查组相比,筛查阴性组肺癌发病风险显著降低(HR 0.80,95%CI 0.65-0.97),全因死亡风险显著降低(HR 0.77,95%CI 0.70-0.85)。
- 筛查阴性组与未筛查组的肺癌特异性死亡风险无显著差异(HR 0.88,95%CI 0.69-1.12)。
- 筛查阴性组肺癌发病风险降低在随访全程持续,前3年最明显。
- 筛查阴性组与低风险组的肺癌发病(HR 0.84,95%CI 0.68-1.03)、肺癌死亡(HR 0.89,95%CI 0.69-1.15)和全因死亡(HR 0.91,95%CI 0.80-1.05)风险相当,但9年累积随访时筛查阴性组肺癌风险略低。
关键数值与推荐
- 与未筛查组相比,筛查阴性组肺癌发病HR 0.80(95%CI 0.65-0.97),全因死亡HR 0.77(95%CI 0.70-0.85),肺癌特异性死亡HR 0.88(95%CI 0.69-1.12)。
- 与低风险组相比,筛查阴性组肺癌发病HR 0.84(95%CI 0.68-1.03),肺癌死亡HR 0.89(95%CI 0.69-1.15),全因死亡HR 0.91(95%CI 0.80-1.05)。
临床怎么用
- 对低剂量CT筛查阴性者,可依据风险分层制定随访间隔,而非统一每年复筛。
- 当前吸烟且筛查阴性者长期肺癌发病风险较高,应加强随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical value of a negative low-dose CT (LDCT) screening result for long-term risk stratification remains unclear, leading to uncertainties in rescreening intervals. RESEARCH QUESTION: What are the long-term risks of lung cancer incidence and mortality among individuals with negative screening results? STUDY DESIGN AND METHODS: This prospective cohort study used data from provincial initiatives (2012-2019) within China's National Lung Cancer Screening Program. Participants 40 to 74 years of age were categorized as nonscreened, negative screening results, positive screening results, or low risk. Inverse probability weighting integrated with Cox proportional hazard models was used to estimate the hazard ratios (HRs) and 95% CIs for lung cancer incidence and mortality. RESULTS: During a median follow-up of 8.61 years, 3,173 incident lung cancers and 2,083 lung cancer deaths occurred among 269,173 participants. Compared with the nonscreened group, the group with negative screening results exhibited a significantly lower risk of lung cancer incidence (HR, 0.80; 95% CI, 0.65-0.97) and all-cause mortality (HR, 0.77; 95% CI, 0.70-0.85), whereas lung cancer-specific mortality did not differ significantly (HR, 0.88; 95% CI, 0.69-1.12). The reduced risk of lung cancer persisted throughout follow-up and was most pronounced during the first 3 years. Although the group with negative screening results exhibited lung cancer incidence (HR, 0.84; 95% CI, 0.68-1.03), lung cancer mortality (HR, 0.89; 95% CI, 0.69-1.15), and all-cause mortality (HR, 0.91; 95% CI, 0.80-1.05) comparable with those in the low-risk group, a slightly lower risk of lung cancer was observed in the group with negative screening results at the 9-year cumulative follow-up. In stratified analyses, individuals who were currently smoking with negative screening results showed a higher long-term risk of lung cancer incidence than those in the low-risk group. INTERPRETATION: Our results show that individuals with negative LDCT screening results generally had long-term risks of lung cancer incidence, mortality, and all-cause mortality comparable with those of the low-risk population, supporting risk-stratified follow-up, rather than uniform annual rescreening.
引用
- Liu H, Yan S, Liu P, et al. Lung Cancer Incidence and Mortality After Negative Low-Dose CT Imaging Screening Results. Chest. 2026. PMID: 42385994. doi:10.1016/j.chest.2026.05.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。